CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for Praxis Precision Medicines Inc is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

Praxis Precision Medicines Inc
99 High Street, 30th Floor
Phone: (617) 300-8460p:617 300-8460 BOSTON, MA  02110  United States Ticker: PRAXPRAX
Business Summary
Praxis Precision Medicines, Inc. is a clinical-stage biopharmaceutical company. It is focused on translating insights from genetic epilepsies into the development of therapies for central nervous system disorders characterized by neuronal excitation-inhibition imbalance. It is applying genetic insights to the discovery and development of therapies for neurological disorders through two platforms, using its understanding of shared biological targets and circuits in the brain. Its platform includes Cerebrum, a small molecule platform, which utilizes deep understanding of neuronal excitability and neuronal networks and applies a series of computational and experimental tools to develop orally available precision therapies, and Solidus, is an antisense oligonucleotide platform, is an efficient, targeted precision medicine discovery and development engine anchored on a proprietary, computational methodology. Its product candidates include ulixacaltamide, PRAX-562, PRAX-628 and elsunersen.

Scores and Ratings
FRISK®
Score		 Z''
Score		 PAYCE®
Score		 DBT
Index		 Moody's
Rating		 Fitch
Rating		 DBRS
Rating
YesYes-Yes---

Financials, News and Filings
Latest
Statement		 Last
Audit
News		 SEC
Filings		 Bankruptcy
Filings		 Suit &
Judgment
Filings		 Tax
Lien
Filings
9/30/202412/31/2023YesYes---

Industries
SIC Code Description
8731 Commercial physical and biological research
2834 Pharmaceutical preparations

Officers and Directors

Title
Name
Age		 Title
Date		 Start
Date
Independent Chairman of the Board DeanMitchell 68 9/1/2020 9/1/2020
President, Chief Executive Officer, Director MarcioSouza 45 4/1/2020 4/1/2020
Chief Financial Officer Timothy E.Kelly 51 1/1/2024 5/25/2021
5 additional Officers and Directors records available in full report.

Business Names
Business Name
PRAX
Praxis Precision Medicines Australia PTY LTD
Praxis Security Corporation

General Information
Number of Employees: 82 (As of 3/1/2024)
Outstanding Shares: 18,637,777 (As of 11/1/2024)
Shareholders: 4
Stock Exchange: NASD
Fax Number: (302) 655-5049


Copyright © 2024 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Tuesday, December 3, 2024